Loading
A phase 3 trial of Pirtobrutinib, Bendamustine and Rituximab in chronic lymphocytic leukaemia, run by Loxo Oncology, Inc., active and no longer recruiting.
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) is a phase 3 interventional study registered as NCT05023980 by Loxo Oncology, Inc., with 309 participants enrolled, started 2021-09-23 and due to reach its primary completion in 2025-07-11. Interventions recorded: Pirtobrutinib, Bendamustine and Rituximab.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Pirtobrutinib, Eli Lilly (incl. Loxo), Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Rituximab, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares Bendamustine, Rituximab, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares Bendamustine, Chronic lymphocytic leukaemia, first treatment, Rituximab, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Pirtobrutinib, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.